Ultragenyx Pharmaceutical (RARE) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Stoke Therapeutics (STOK) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, losing 21.5% versus a loss of 50.5%. Over five years, STOK leads with a +1.8% price change compared with -80.9% for RARE. Stoke Therapeutics is the larger company by market cap ($1.59 billion vs $1.53 billion), about 1.0 times the size.
Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -85.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RARE | STOK |
|---|---|---|
| Share price | $15.55 | $24.61 |
| Market cap | $1.53B | $1.59B |
| 1-day change | +1.70% | +2.76% |
| YTD return | -33.52% | -24.54% |
| 1-year return | -50.45% | -21.48% |
| 5-year return | -80.89% | +1.83% |
| Forward P/E | 22.98 | — |
| EPS (TTM) | $-5.82 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $673.00M | $184.42M |
| Revenue growth (YoY) | +20.18% | +404.50% |
| Net income (latest FY) | $-575.00M | $-6.88M |
| Operating margin | -79.49% | -11.16% |
| Net margin | -85.44% | -3.73% |
| 52-week high | $39.89 | $40.22 |
| 52-week low | $12.73 | $20.32 |
| Distance from 52-week high | -61.02% | -38.81% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +80.39% | +88.79% |
| Average volume | 3.87M | 855.13K |
| Shares outstanding | 98.59M | 64.53M |
| Employees | 1,371 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STOK has outperformed RARE by 29.0 percentage points over the past year.
- Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -85.4 cents for Ultragenyx Pharmaceutical.
- Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +20.18%).
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
RARE vs STOK FAQ
Which is bigger, Ultragenyx Pharmaceutical or Stoke Therapeutics?
Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.59B compared with $1.53B for Ultragenyx Pharmaceutical (RARE).
Which stock has performed better over the past year, RARE or STOK?
STOK returned -21.48% over the past 12 months, compared with -50.45% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Ultragenyx Pharmaceutical and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.